BlackRock, Inc. Increases Stake in LENZ THERAPEUTICS, INC.

BlackRock, Inc. has filed a Schedule 13G with the SEC, disclosing an increased ownership stake in LENZ THERAPEUTICS, INC. As of the effective date of October 17, 2025, BlackRock, Inc. beneficially owns 1,442,864 shares of common stock, representing 5.1% of the total outstanding shares. This marks a significant increase from their previous holdings, with a value change of $951,550,880.28 and a shares change of 819,483. The filing indicates that BlackRock, Inc. holds these shares in the ordinary course of business and not for the purpose of influencing control of the issuer. The filing also includes certifications and exhibits, such as a Power of Attorney and details on subsidiary identification.